10.16
+0.76
(8.09%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 9.44 - 10.20 |
| 52 week | 2.75 - 10.20 |
| Open | 9.45 |
| Vol / Avg. | 728,464.00/434,179.00 |
| Mkt cap | 292.25M |
| P/E | - |
| Div/yield | - |
| EPS | -0.81 |
| Shares | 28.77M |
| Beta | 1.25 |
| Inst. own | 43% |
Events
Aug 5, 2013
Q2 2013 TearLab Corp Earnings Release
Jun 7, 2013
TearLab Corp Annual Shareholder Meeting
- 8:30AM EDT -
May 13, 2013
Q1 2013 TearLab Corp Earnings Conference Call
May 13, 2013
Q1 2013 TearLab Corp Earnings Release
Mar 20, 2013
Q4 2012 TearLab Corp Earnings Conference Call
Mar 18, 2013
TearLab Corp at Roth Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -226.69% | -487.68% |
| Operating margin | -206.27% | -303.84% |
| EBITD margin | - | -268.99% |
| Return on average assets | -57.67% | -111.38% |
| Return on average equity | -88.59% | -189.67% |
| Employees | 48 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 200, 7360 Carroll Rd
SAN DIEGO, CA 92121
United States - Map
+1-858-4556006 (Phone)
+1-858-8120540 (Fax)
SAN DIEGO, CA 92121
United States - Map
+1-858-4556006 (Phone)
+1-858-8120540 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
TearLab Corp. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). TearLab Research, Inc., its wholly owned subsidiary, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (i.e. glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company's business. Its TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of three components: the TearLab disposable, the TearLab Pen and the TearLab Reader.
Officers and directors
| Elias Vamvakas | Chairman of the Board, Chief Executive Officer, Secretary | |
| Robert Walder | Vice President - Operations | |
| Stephen Zmina | Vice President - Manufacturing & Engineering | |
| Anthony E. Altig | Independent Director | |
| Thomas N. Davidson Jr. | Independent Director | |
| Adrienne L. Graves Ph.D. | Independent Director | |
| Paul M. Karpecki | Independent Director | |
| Richard L. Lindstrom M.D. | Independent Director |